IP Library Granted Patent US 11,739,308
Granted Patent B2
US 11,739,308 · App. 16/493,464 · Granted Aug 29, 2023

Cas13b orthologues CRISPR enzymes and systems

Inventors: David Benjamin Turitz Cox (Cambridge, MA); Neena Pyzocha (Cambridge, MA); Feng Zhang (Cambridge, MA)
Assignees: The Broad Institute, Inc.; Massachusetts Institute of Technology
C12N9/22C12N15/86C12N2310/20C12N2800/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,739,308
App. No.
16/493,464
Granted
Aug 29, 2023
Kind
B2
Abstract

The invention provides for systems, methods, and compositions for targeting nucleic acids. In particular, the invention provides non-naturally occurring or engineered RNA-targeting systems comprising a novel RNA-targeting Cas13b effector protein and at least one targeting nucleic acid component like a guide RNA or crRNA.

Claims (13)

1. An engineered composition comprising:

i) a Cas13b effector protein comprising the amino acid sequence of SEQ ID NO:32, and

ii) an engineered guide RNA,

wherein the engineered guide RNA is capable of forming a CRISPR-Cas complex with the Cas13b effector protein and comprises a) a guide sequence that directs sequence specific binding to a target RNA sequence other than a naturally occurring Prevotella intermedia Cas13b protospacer and that reprograms the CRISPR-Cas complex to bind said target RNA sequence, and b) a direct repeat sequence.

2. The engineered composition of claim 1 , which comprises an accessory protein that enhances the activity of the Cas13b effector protein or represses activity of the Cas13b effector protein.

3. The engineered composition of claim 2 , wherein the accessory protein that enhances the activity of the Cas13b effector protein is a csx28 protein.

4. The engineered composition of claim 2 , wherein the accessory protein that represses the activity of the Cas13b effector protein is a csx27 protein.

5. The engineered composition of claim 1 , which comprises two or more engineered guide RNAs.

6. The engineered composition of claim 1 , wherein the engineered guide RNA hybridizes to a target RNA sequence in a prokaryotic cell.

7. The engineered composition of claim 1 , wherein the engineered guide RNA hybridizes to a target RNA sequence in a eukaryotic cell.

8. The engineered composition of claim 1 , wherein the Cas13b effector protein comprises one or more nuclear localization signals (NLSs).

9. The engineered composition of claim 2 , wherein the Cas13b effector protein and the accessory protein are from the same organism.

10. The engineered composition of claim 2 , wherein the Cas13b effector protein and the accessory protein are from different organisms.

Assignments (4)
CONFIRMATORY LICENSE Recorded Aug 11, 2023
From: BROAD INSTITUTE INC
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 064572/0281 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 25, 2019
From: PYZOCHA, NEENA
To: MASSACHUSETTS INSTITUTE OF TECHNOLOGY
Reel/Frame 050487/0717 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 25, 2019
From: ZHANG, FENG
To: THE BROAD INSTITUTE, INC.; MASSACHUSETTS INSTITUTE OF TECHNOLOGY
Reel/Frame 050487/0838 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 25, 2019
From: COX, DAVID BENJAMIN TURITZ
To: MASSACHUSETTS INSTITUTE OF TECHNOLOGY
Reel/Frame 050487/0942 →
Continuity (3)
Provisional Application 62566829 · Oct 2, 2017
Provisional Application 62471710 · Mar 15, 2017
Related Publication 20200131488A1 · Apr 30, 2020
Cited By (1)
US 12,215,318